New nivolumab data in gastric cancer ups 12m OS to 26.6% from 10.9% w placebo. Median OS gains more modest, 5m v 4m: https://t.co/l17DpnUrCM
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/822490642341359620
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nL9dMr via IFTTT
-
by Demin Li, Carol Bentley, Jenna Yates, Maryam Salimi, Jenny Greig, Sarah Wiblin, Tasneem Hassanali, Alison H. Banham Therapeutic monoclon...
-
Background Although pneumonia is a leading cause of death in New York City (NYC), limited data exist about the settings in which pneumonia ...
-
Vol.30 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nItCSB via IFTTT
-
Summary We tested whether prophylactic droperidol and ondansetron, in combination with a moderate dose of dexamethasone, were equally effe...
-
Abstract Background Head and neck extirpations requiring reconstruction are challenging surgeries with high postoperative complication r...
-
Web version of a book about Subversion. Work in progress, however already very complete. The book should be published by O'Reilly and As...
-
ACS Nano DOI: 10.1021/acsnano.6b08567 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oNpdhD via...
-
Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea syndrome (OSA) are both highly prevalent, which implies that both d...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου